Cabozantinib granted breakthrough therapy designation in the US for previously treated radioactive iodine-refractory differentiated thyroid cancer

An interim analysis of the Phase III COSMIC-311 trial found cabozantinib reduced risk of disease progression or death compared to placebo (HR 0.22; 96% CI 0.13-0.36; p<0.0001), in patients with disease progression following ≤2 prior VEGFR-targeted therapies.

Biospace Inc.